Novo Nordisk’s stock hit a 52-week low after its REDEFINE 4 trial failed to demonstrate non-inferiority in weight loss compared to Eli Lilly’s tirzepatide, marketed under the Zepbound and Mounjaro brands.The trial showed a weight loss of 20.2% with CagriSema versus 23.6% with tirzepatide, leading to a significant drop in Novo Nordisk shares.The REDEFINE 4 trial involved 809 subjects over 84 weeks, and while CagriSema demonstrated a safe profile, the results did not meet expectations.William Blair analyst An ...

Core Viewpoint - Biogen Inc. plans to invest an additional $2 billion in its manufacturing operations in North Carolina's Research Triangle Park, building on approximately $10 billion already invested, to support its late-stage clinical pipeline [1][2]. Investment Plans - The upcoming investment will enhance Biogen's capabilities in antisense oligonucleotide (ASO) production, establish multi-platform fill finish capabilities, and modernize manufacturing technologies through advanced automation and artificial intelligence [2][3]. - Biogen's manufacturing footprint in the U.S. has been crucial for its success, and this investment aims to modernize and expand its capabilities to ensure a resilient supply for patients [3]. Employment and Production - Biogen is the largest biotechnology employer in North Carolina, employing over 1,500 manufacturing and technical staff, along with more than 400 skilled contractors [4]. - More than 90% of Biogen's commercial medicines undergo manufacturing and quality control testing in the U.S. [4]. Industry Context - The U.S. government is promoting domestic pharmaceutical manufacturing, with President Trump's executive order aimed at streamlining the establishment of new production sites amid tariff uncertainties [5]. - Other pharmaceutical companies are also increasing their investments in U.S. manufacturing, with notable commitments from Eli Lilly, Thermo Fisher Scientific, and Novartis, among others [6][7][8][9].